July 19, 2022 02:19 PM EDTUpdated July 21, 02:35 PM
R&D
FDA+

MD­MA psy­chother­a­py tri­al put on pause af­ter Health Cana­da in­spec­tion

Tyler Patchen

News Reporter

A Cana­di­an clin­i­cal tri­al in­ves­ti­gat­ing MD­MA-as­sist­ed psy­chother­a­py has been put on hold by Health Cana­da over some stark breaks in clin­i­cal good prac­tices.

Ac­cord­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times